## COR: Cencora, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.7% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($330.22)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Gabelli Funds LLC Reduces Holdings in Cencora, Inc. $COR**
- Source: MarketBeat | 20251209T094529 | Neutral | Relevance: 99%
-  Gabelli Funds LLC decreased its stake in Cencora, Inc. (NYSE:COR) by 6.6% in the second quarter, selling 3,355 shares and now owning 47,770 shares valued at approximately $14.32 million. Concurrently, other institutional investors adjusted their positions, and company insiders, including CEO Robert P. Mauch and Chairman Steven H. Collis, sold significant shares. Despite these reductions, analysts maintain a "Moderate Buy" consensus rating for Cencora with an average target price of $373.50, and the company recently increased its quarterly dividend.

**2. Here's Why You Should Add Cencora Stock to Your Portfolio Now**
- Source: TradingView | 20251210T140752 | Bullish | Relevance: 99%
-  Cencora, Inc. (COR) is positioned for growth due to its strong U.S. Healthcare Solutions business and strategic product launches, despite concerns about international segment weakness and GLP-1 growth moderation. The company has seen significant stock appreciation and positive estimate revisions for fiscal 2026, driven by its acquisition of Retina Consultants of America and ongoing digital transformation. These factors contribute to a bullish outlook for COR's financial performance.

**3. Lombard Odier Asset Management USA Corp Invests $3.16 Million in Cencora, Inc. $COR**
- Source: MarketBeat | 20251209T134716 | Somewhat-Bullish | Relevance: 98%
-  Lombard Odier Asset Management USA Corp recently acquired a new stake in Cencora, Inc. (NYSE:COR) by purchasing 10,534 shares worth approximately $3.16 million during the second quarter. This investment highlights institutional interest in Cencora, with hedge funds and institutional investors collectively owning a significant portion of the company's stock. The article also details recent insider selling activities, Cencora's financial performance, dividend increase, and analyst ratings.

**4. JPMorgan raises Cencora (COR) price target after financial model update**
- Source: MSN | 20251210T000920 | Bullish | Relevance: 97%
- JPMorgan has raised its price target for Cencora (COR) following an update to its financial model. The specific details of the financial model update and the new price target are not provided in this snippet.

**5. Is Cardinal Health Stock Outperforming the Nasdaq?**
- Source: inkl | 20251210T130730 | Somewhat-Bullish | Relevance: 73%
- Cardinal Health (CAH) has significantly outperformed the Nasdaq Composite ($NASX) over the past three months, six months, and 52 weeks, driven by strong sentiment and solid earnings. The healthcare services and products firm reported a 22% year-over-year revenue increase and a 36% non-GAAP EPS increase in Q1 fiscal 2026, leading to a raised outlook. Analysts maintain a "Strong Buy" rating with an expected upside.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $400 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (+4.1%)
- Blackrock Inc.: 10.2% (+5.7%)
- JPMORGAN CHASE & CO: 4.8% (+139.5%)
- State Street Corpora: 4.7% (+9.3%)
- Price (T.Rowe) Assoc: 4.0% (-0.9%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.90 indicates undervaluation relative to growth. Quality metrics strong (ROE 124%). Balance sheet: $2.9B free cash flow. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $66.8B |
| Beta | 0.63 |
| 52W Range | $223.92 - $377.54 |
| Short Interest | 4.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.90 |
| Forward P/E | 17.6 |
| Current P/E | 19.5 |
| YoY Growth | 10.6% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -6.5% to -0.7% (+5.9% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.6pp (needs >3.0% for momentum thesis). MRS_5 turning positive (1.3%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.15x) but short-term weakness (below SMA20). MACD histogram bearish (-3.58), momentum weakening. RSI neutral at 46.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.65% (CS: 30) | Neutral |
| RSI_14 | 46.4 | Neutral |
| MACD Histogram | -3.58 | Bearish |
| vs SMA20 | 0.969x | Below |
| vs SMA50 | 1.009x | Above |
| vs SMA200 | 1.147x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $344.50
- **Stop Loss:** $330.22 (4.1% risk)
- **Target:** $358.78 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 96
- **Position Value:** $33,072.00
- **Portfolio %:** 33.07%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-04 (Est: $4.07)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.79 | $3.84 | +1.4% |
| 2025Q2 | $3.84 | $4.00 | +4.2% |
| 2025Q1 | $4.10 | $4.42 | +7.9% |
| 2024Q4 | $3.52 | $3.73 | +6.0% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*